Clinical trials
Metastatic Breast Cancer ( HER2 Negative) clinical trials
Below are recruiting metastatic breast cancer ( her2 negative) clinical trials, each written for real people, not researchers. We’re tracking 486 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06450314RecruitingPhase 2
De-escalating treatment for advanced HER2-positive breast cancer
This trial tests whether it's safe to reduce or stop some cancer treatments for people whose advanced HER2-positive breast cancer has been well-controlled for at least 2 years and has no detectable cancer cells in blood tests.
RennesAges 18 years+ - NCT06441890RecruitingPhase 2
Personalized chemo before breast cancer surgery
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Chicago, IllinoisAges 18 years+ - NCT06435351RecruitingEarly Phase 1
Personalized vaccine for high-risk triple-negative breast cancer
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06439693RecruitingPhase 2
Sequential therapy for newly diagnosed HER2+ breast cancer that has spread
This trial tests a sequence of targeted therapies for people newly diagnosed with HER2-positive breast cancer that has spread to other parts of the body. The goal is to find a treatment plan that can potentially cure the cancer.
Boston, MassachusettsAges 18 years+ - NCT06435429RecruitingPhase 3
Zanidatamab vs trastuzumab for HER2+ breast cancer
This study compares a new drug called zanidatamab against trastuzumab (Herceptin), both given with a chemotherapy of your doctor's choice. It is for people with HER2-positive breast cancer that has spread and who have already tried T-DXd treatment.
Phoenix, ArizonaAges 18 years+ - NCT06417801Recruiting
Study of ESR1 gene changes in blood in advanced breast cancer
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Salvador, Estado de BahiaAges 18–100 - NCT06414733RecruitingPhase 1
Vaccine for advanced breast or esophageal cancer
This trial tests a vaccine that targets HER2 protein on cancer cells. It is for people with advanced breast or esophageal cancer whose tumors have certain markers. The vaccine may help your immune system fight the cancer.
Indianpolis, IndianaAges 18 years+ - NCT06409390RecruitingPhase 2
Sequential therapy based on tumor evolution for breast cancer
This trial tests a sequence of different treatments for breast cancer that has spread, based on how the cancer evolves. The goal is to find a personalized treatment plan that may work better over time.
Tampa, FloridaAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Gilbert, ArizonaAges 18 years+ - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+ - NCT06388122Recruiting
Blood test study for HR+ breast cancer treatment monitoring
This study looks at a blood test (DiviTum TKa) to see how well it measures treatment response in people with hormone receptor-positive (HR+) breast cancer that has spread. The test may help doctors know if a treatment is working.
Jacksonville, FloridaAges 18 years+ - NCT06369831RecruitingPhase 2
Imaging test for HER2 in metastatic cancer
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
Innsbruck, TyrolAges 18 years+ - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Birmingham, AlabamaAges 18 years+ - NCT06374459RecruitingPhase 1/Phase 2
Zunsemetinib and capecitabine for breast cancer with bone spread
This trial tests a new drug called zunsemetinib combined with the chemotherapy capecitabine for people with hormone receptor-positive, HER2-negative breast cancer that has spread to the bones. The goal is to see if this combination can better control the cancer.
Westwood, KansasAges 18 years+ - NCT06365788RecruitingPhase 2
Bicalutamide and Abemaciclib for AR-positive Triple-negative Breast Cancer
This trial tests a combination of two oral drugs—bicalutamide and abemaciclib—for people with a specific type of advanced triple-negative breast cancer that grows in response to androgen hormones (AR-positive). The goal is to see if this treatment can shrink tumors or slow disease progression.
AntwerpAges 18 years+ - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT06312176RecruitingPhase 3
Study of new drugs for HR+/HER2- advanced breast cancer
This trial tests two new drugs (sacituzumab tirumotecan and pembrolizumab) against standard treatments for a type of advanced breast cancer that is hormone receptor positive and HER2 negative. It's for people whose cancer has worsened despite hormone therapy with a CDK4/6 inhibitor.
Chandler, ArizonaAges 18 years+ - NCT06298084RecruitingPhase 1/Phase 2
HER3-DXd for Advanced Breast Cancer After T-DXd
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
Villejuif, FranceAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06260033RecruitingPhase 2
Radiation Therapy for Oligoprogressive ER+ Breast Cancer
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
Duarte, CaliforniaAges 18 years+ - NCT06263543RecruitingPhase 2
Sequencing antibody-drug conjugates in ER+, HER2-low breast cancer
This trial tests different sequences of antibody-drug conjugates (a type of targeted chemotherapy) for people with ER-positive, HER2-low or ultra-low metastatic breast cancer that has stopped responding to hormone therapy and has progressed on Enhertu. You must have had 1–4 prior chemotherapies for metastatic disease.
Miami, FloridaAges 18 years+ - NCT06230055RecruitingPhase 4
Chemotherapy for breast cancer that has spread to the spinal fluid
This trial tests a chemotherapy drug given directly into the spinal fluid for people with HER2-negative breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). It may help when standard treatments have stopped working or caused too many side effects.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Metastatic Breast Cancer ( HER2 Negative) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic breast cancer ( her2 negative)?
- Yes. Clin2 currently lists 486 recruiting metastatic breast cancer ( her2 negative) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic breast cancer ( her2 negative) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic breast cancer ( her2 negative) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HER2-negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- HER2-positive Metastatic Breast Cancer
- Metastatic HER2-Negative Breast Carcinoma
- HR-positive, HER2-negative Advanced Breast Cancer
- Hormone Receptor Positive / HER2-negative Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.